Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

NCT06124963 is registered in ClinicalTrials.gov with Shanghai Jiatan Pharmatech Co., Ltd as lead sponsor.

NCT NCT06124963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06124963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2023
Completion date
December 9, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric type adenocarcinoma (gas) with stk11 mutation